Joseph M. Thomas

Allergy and Immunology
9811 Mallard Dr
Suite No.114
Laurel, MD 20708

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway.

Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway.

Journal: Human molecular genetics
Published: March 10, 2022

A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.

A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.

Journal: Cells
Published: December 03, 2020

GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.

GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.

Journal: Journal of cellular physiology
Published: November 04, 2019

The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.

The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.

Journal: Biochemistry and cell biology = Biochimie et biologie cellulaire
Published: December 22, 2017

68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment.

68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment.

Journal: Frontiers in aging neuroscience
Published: November 21, 2016

Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.

Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.

Journal: Human molecular genetics
Published: October 06, 2015

A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.

A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.

Journal: PloS one
Published: November 13, 2014

Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.

Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.

Journal: Human molecular genetics
Published: July 05, 2014

From fat fruit fly to human obesity.

From fat fruit fly to human obesity.

Journal: Physiology & behavior
Published: December 06, 2013
Showing 1-9 of 9

Last Updated: 09/26/2026